Monographie - Irinotecan - Stabilis 4.0

Ultimele actualizari :
08/05/2024

Citostatic

Irinotecan

Injectabil

Stabilitatea in solutie

Stabilitatea in amestec

Factorii care influenteaza stabilitatea

Compatibilitate

Microunde

Bibliografie

Pdf

Formula chimica

Denumirea comerciala

Denumirea comerciala

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Asinib	Mexic
Axinotecan	Germania
Campto	Africa de Sud, Austria, Belgia, Croatia, Danemarca, Elvetia, Emiratele Arabe Unite, Finlanda, Franta, Grecia, India, Iran, Irlanda, Italia, Japonia, Luxemburg, Malaezia, Marea Britanie, Maroc, Norvegia, Olanda, Polonia, Portugalia, Spania, Suedia, Tailanda, Tunisia, Turcia, Ungaria
Camptosar	Brazilia, Canada, SUA
Irinoliquid	Austria
Irnocam	Brazilia

Bibliografie

Injectabil

Bibliografie : Irinotecan

	Tip	Publicare
1423	Ziar	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1617	Ziar	Li WY, Koda RT. Stability of irinotecan hydrochloride in aqueous solutions. Am J Health-Syst Pharm 2002 ; 59: 539-544.
1662	Ziar	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1918	Ziar	Dodds HM, Craik DJ, Rivory LP. Photodegradation of irinotecan (CPT-11) in aqueous solutions : identification of fluorescent products and influence of solution composition. J Pharm Sci 1997 ; 86, 12: 1410-1416.
1920	Ziar	Akimoto K, Kaway A, Ohya K et al. Photodegradation reactions of CPT-11, a derivative of campothecion, part i: chemical structure of main degradation products in aqueous solution. Drug Stability 1996 ; 1: 118-122.
1921	Ziar	Akimoto K, Kawai A, Ohya K. Photodegradation reactions of CPT-11, a derivative of campothecion, part ii: photodegradation behaviour of CPT-11 in aqueous solution. Drug Stability 1996 ; 1; 141-146.
1953	Ziar	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1976	Ziar	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 238-241.
2027	Ziar	Walker SE, Shirley L, Puodziunas A. Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers. Can J Hosp Pharm 2005 ; 58: 212-222.
2143	Ziar	Dodds HM, Robert J, Rivory LP. The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry. J Pharm Biomed Anal 1998 ; 17: 785-792.
2168	Ziar	Ozdemir FA, Anilanmert B, Pekin M. Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution. Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2241	Ziar	Thiesen J, Krämer I. Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags. J Oncol Pharm Practice 2000 ; 6, 3: 115-121.
2340	Ziar	Walker S.E, Law S, Puodziunas A. Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers Can J Hosp Pharm 2005 ; 58, 4: 212-222.
2671	Ziar	Kaiser J, Thiesen J, Krämer I. Stability of irinotecan-loaded eluting beads (DC Bead) used for transarterial chemoembolization. J Oncol Pharm Practice 2010 ; 16: 53-61.
3129	Laborator	Irinotécan (Campto®) – Résumé des caractéristiques du produits Pfizer 2008
3369	Laborator	Levofolinate de sodium Medac - Résumé des caractéristiques du produits MEDAC France 2011
3670	Ziar	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3873	Ziar	Tan X, Hu J. Incompatibility between irinotecan and fluorouracil injections Am J Health-Syst Pharm 2016 ; 73:755.

Mentions Légales